Maxim Group reissued their buy rating on shares of BeyondSpring (NASDAQ:BYSI) in a research report sent to investors on Thursday morning. Maxim Group currently has a $52.00 price objective on the stock.
“BeyondSpring will be presenting P2 data (N=55) from study 105 comparing lead asset plinabulin to Neulasta on incidence of neutropenia. The data (detailed below) demonstrates that a single dose of Plinabulin protects against neutropenia at the same rate as Neulasta while producing lower rates of bone pain.”,” Maxim Group’s analyst wrote.
Other analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of BeyondSpring from a hold rating to a buy rating and set a $30.00 target price on the stock in a research report on Thursday, April 5th. HC Wainwright set a $60.00 target price on shares of BeyondSpring and gave the company a buy rating in a research report on Tuesday, April 3rd. Finally, ValuEngine upgraded shares of BeyondSpring from a sell rating to a hold rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $49.60.
BeyondSpring (NASDAQ:BYSI) last announced its earnings results on Tuesday, April 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.06). equities analysts expect that BeyondSpring will post -2.8 EPS for the current fiscal year.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.